You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HR breast cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HR+/HER2-breast Cancer Trial (Standard endocrine therapy plus Apatinib)

Not yet recruiting
  • HR+/HER2-breast Cancer
  • Standard endocrine therapy plus Apatinib
  • (no location specified)
Jun 2, 2023

Early-stage Breast Cancer, HER2 Positive Breast Cancer, Hormone Receptor Positive Trial (Neratinib, Loperamide, Colesevelam)

Not yet recruiting
  • Early-stage Breast Cancer
  • +2 more
  • (no location specified)
Aug 5, 2022

HR Positive HER2 Negative Advanced Breast Cancer Trial in Tianjin (Chidamide)

Recruiting
  • HR Positive HER2 Negative Advanced Breast Cancer
  • Tianjin, China
    天津市肿瘤医院
May 26, 2023

Breast Cancer Trial in Wuhan (Adebrelimab, dalpiciclib)

Recruiting
  • Breast Cancer
  • Wuhan, Hubei, China
    Tongji Hospital Affiliated of Tongji Medical College Huazhong Un
Nov 20, 2023

Advanced Hormone Receptor Positive (HR+) Breast Cancer Trial (everolimus)

No longer available
  • Advanced Hormone Receptor Positive (HR+) Breast Cancer
  • (no location specified)
Nov 26, 2021

HER2 Low Breast Carcinoma Trial (SHR-A1811 for injection)

Not yet recruiting
  • HER2 Low Breast Carcinoma
  • SHR-A1811 for injection
  • (no location specified)
Jun 12, 2023

Breast Cancer Trial in Tianjin (Pyrrolidine?trastuzumab?AI)

Recruiting
  • Breast Cancer
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Jun 1, 2023

Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed Trial in Hangzhou (dalpiciclib;

Recruiting
  • Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
  • dalpiciclib; fluvestrant; compound gossypol acetate tablets
  • Hangzhou, Zhejiang, China
    zhejiangCH
Nov 9, 2023

Ribociclib in Combination With Hormonal Therapy in HR+/HER2-

Not yet recruiting
  • Breast Cancer
  • ribociclib
  • (no location specified)
Oct 10, 2023

Breast Cancer Trial in Tianjin (Dalcelli?Exemestane?Gosserine, Docetaxel for injection?Epirubicin HCl for

Recruiting
  • Breast Cancer
  • Tianjin, Tianjin, China
    Jie Ge
Aug 20, 2023

Clinical Outcomes in HR+ and HER2-low/Negative Breast Cancer

Active, not recruiting
  • Hormone-receptor-positive Breast Cancer
  • +2 more
  • No drug
  • Cambridge, Massachusetts
    ConcertAI database
Sep 8, 2023

Metastatic Breast Cancer Trial (SKB264, Eribulin, Capecitabine)

Not yet recruiting
  • Metastatic Breast Cancer
  • (no location specified)
Oct 7, 2023

Breast Cancer Trial (Disitamab Vedotin+Anlotinib)

Not yet recruiting
  • Breast Cancer
  • Disitamab Vedotin+Anlotinib
  • (no location specified)
Aug 14, 2023

HR+/HER2- Breast Cancer Trial (Tucidinostat, nab-paclitaxel)

Not yet recruiting
  • HR+/HER2- Breast Cancer
  • (no location specified)
Nov 21, 2022

Breast Cancer Metastatic Cancer Trial in Shanghai (Apatinib, Dalpiciclib, Fulvestrant/AI)

Recruiting
  • Breast Cancer Metastatic Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Feb 26, 2023

Breast Cancer Trial in Shantou (dose-dense nab-paclitaxel followed by EC)

Recruiting
  • Breast Cancer
  • dose-dense nab-paclitaxel followed by EC
  • Shantou, Guangdong, China
    Shantou Central Hospital
Feb 4, 2023

Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma Trial in Guangzhou (Pyrotinib,

Not yet recruiting
  • Breast Cancer Invasive
  • +3 more
  • Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
  • Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nov 17, 2023

Breast Cancer Metastatic Cancer Trial in Shanghai (Fluzoparib, Dalpiciclib, Fulvestrant/AI)

Recruiting
  • Breast Cancer Metastatic Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Feb 26, 2023

HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)

Recruiting
  • HR+/HER2- Advanced Breast Cancer
  • Targeted Therapy
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Aug 1, 2023

Breast Cancer Trial in Chengdu (Dalpiciclib combined with Letrozole)

Not yet recruiting
  • Breast Cancer
  • Dalpiciclib combined with Letrozole
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Aug 3, 2023

Breast Tumors Trial in Guangzhou (Trilaciclib, Epirubicin, Cyclophosphamide)

Not yet recruiting
  • Breast Neoplasms
  • Guangzhou, Gangdong, China
    Sun-yat sen university cancer center
Jul 30, 2023

Hormone Receptor-positive Advanced Breast Cancer Trial (chidamide,fulvestrant)

Not yet recruiting
  • Hormone Receptor-positive Advanced Breast Cancer
  • (no location specified)
Apr 12, 2023

Breast Cancer Trial in Yantai (pyrotinib combined with trastuzumab, dalpiciclib and letrozole)

Recruiting
  • Breast Cancer
  • pyrotinib combined with trastuzumab, dalpiciclib and letrozole
  • Yantai, Shandong, China
    Yantai Yuhuangding Hospital
Mar 23, 2023

Breast Cancer Trial (Fluzoparib, Anastrozole, Letrozole)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Jun 5, 2023

Breast Cancer Trial in United States (radiation, drug, biological)

Recruiting
  • Breast Cancer
  • Focal Radiation therapy
  • +2 more
  • Los Angeles, California
  • +6 more
Apr 29, 2022